A Clinical Trial to Investigate the Effect of a Short Duration Infusion of Obinutuzumab in Patients with Previously Untreated Advanced Follicular Lymphoma (MO40597 study)

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma (MO40597 study)

  • Follicular Lymphoma
Trial Status:

Completed

This trial runs in
Cities
  • Austin
  • Barcelona
  • boulder
  • Cardiff
  • Ceará
  • Chemnitz
  • Chiba
  • Chuo City
  • Cádiz
  • Dessau-Roßlau
  • Dordrecht
  • Eugene
  • Farmington
  • Florham Park
  • Frankfurt am Main
  • gasteiz
  • Groningen
  • Hamburg
  • Kobe
  • Koto City
  • Köln
  • Landshut
  • Lübeck
  • Madrid
  • Maryland
  • Murcia
  • Osakasayama
  • Portsmouth
  • Rio Grande do Sul
  • Santa Catarina
  • Sapporo
  • São Paulo
  • Truro
Trial Identifier:

NCT03817853 MO40597

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with previously untreated advanced follicular lymphoma (FL). The study has two phases: in the first phase, participants will receive the first cycle of obinutuzumab-based chemotherapy (G-chemo) induction therapy as usual with the first three infusions of obinutuzumab (1000 mg) administered at the regular infusion rate on Day 1, 8, and 15 of cycle 1. Phase 2 starts when participants who do not experience any Grade ≥ 3 infusion related reactions during the first cycle receive their first obintuzumab infusion given at the faster infusion rate in Cycle 2. For Cycle 2, Day 1 and all other following infusions (including maintenance), obinutuzumab will be administered at a faster infusion of 90-minute SDI, as long as the participant does not experience any Grade ≥ 3 infusion related reactions. The investigator is free to choose the chemotherapy for each participant (bendamustine, CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone/methylprednisolone], or CVP [cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone]). The total number of cycles of G-chemo induction therapy and the cycles length depends on the chemotherapy chosen for each participant.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT03817853 , MO40597 , 2018-003255-38 Trial Identifier
      All Gender
      ≥18 Years Age
      No Healthy Volunteers

      How does the MO40597 clinical trial work?
      This clinical trial is recruiting people who have a specific type of blood cancer called ‘follicular lymphoma’. This type of cancer is caused by cells that usually fight infection called white blood cells (or immune cells) that multiply out of control.

      This study is testing whether an approved medicine called obinutuzumab can be given through a drip into the vein (called an intravenous infusion) at a faster infusion rate, so that the obinutuzumab infusion is given within approximately 90 minutes instead of the usual 4 hours (i.e. regular infusion rate).

      How do I take part in this clinical trial?
      To be able to take part in this clinical trial, you must not have already been given any medicine for your cancer.

      If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor.

      If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor who will give you all the information you need to make your decision about taking part in the clinical trial. You will also find the clinical trial locations at the top of this page.

      You will have some tests to make sure you will be able to take the treatments given in this clinical trial. These are the same tests that you would have as part of your regular care for follicular lymphoma, regardless of whether you take part in this study or not. If you have had some of these tests recently, they may not need to be done again.

      Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial and what other treatments are available so that you may decide if you still want to take part. While taking part in the clinical trial, both men and women (if you are not currently pregnant but can become pregnant) will need to agree to either not have heterosexual intercourse or use contraceptive methods for safety reasons whilst receiving treatment and for some time afterwards. If you are a woman and decide to use contraceptive methods, you will need to continue using contraception up to 18 months after last clinical trial treatment. If you are pregnant you will not be able to participate in this clinical trial. If you are a man and decide to use contraceptive methods, you will need to continue using contraception up to 3 months after clinical trial last treatment.

       

      What treatment will I be given if I join this clinical trial?
      All patients in this study will be given a treatment called obinutuzumab and chemotherapy. Which chemotherapy you receive will be decided by the clinical trial doctor. Before your treatment begins, you will be given a combination of medicines (called premedication) that will reduce the risk of having side effects to obinutuzumab and chemotherapy.

      • For the first part of the study, everyone will receive obinutuzumab and chemotherapy every 3 to 4 weeks (1 cycle) for 24 to 32 weeks (6 to 8 cycles). This is called ‘induction’ therapy. Your doctor will decide which chemotherapy is best for you.
      • During the first cycle of treatment, everyone will receive obinutuzumab on Days 1, 8 and 15. For every following cycle, you will receive obinutuzumab on Day 1 only.
      • This first cycle of obinutuzumab treatment will be given at the regular infusion rate (4 hours) and doctors will look for any side effects (known as infusion-related reactions). To reduce the chance that you experience an infusion-related reaction, the clinical trial doctor may give you some premedication (acetaminophen, to reduce fever and chills, and an antihistamine and a corticosteroid) before the infusion.
      • Infusion related reactions may include fever (high body temperature), chills (cold shivers), rash, low blood pressure, and difficulty breathing, among others. Most infusion-related reactions are mild or moderate, but severe, life-threatening reactions can occur.
      • If you do not have any infusion-related reactions (or they were very mild), your second cycle of treatment will be given at a faster infusion rate (approximately 90 minutes). This will continue for the rest of the infusions you receive in the study as long as you do not have any infusion-related reactions in later cycles.
      • If you experience a moderate or severe infusion-related reaction, your next cycle of treatment will remain at the regular infusion rate (4 hours). Your doctor may increase the speed of treatment in later cycles if they feel it is safe to do so.
      • If your disease is responding to the treatment after completing the induction therapy, you will receive additional treatment with obinutuzumab alone (i.e. without chemotherapy) every 8 weeks for up to 2 years at the faster infusion rate. This is called ‘maintenance therapy’.
      • If at any stage your cancer does not respond to the treatment, or you experience life threatening side effects, your doctor may decide to stop the treatment and you will enter the safety-monitoring follow-up phase where you will be seen once by the clinical trial doctor 3 months after you receive your last treatment.

      How often will I be seen in follow-up appointments, and for how long?
      You will be given the trial treatment for as long as it can help you for up to 2 years. You are free to stop this treatment at any time. During your treatment, you will be seen regularly by the clinical trial doctor to see how your cancer is responding to the treatment and if you are experiencing any side effects. After you receive your last treatment, your next and final study visit will be 3 months later when you will be seen by the clinical trial doctor. This will include a hospital visit where you will be given a physical examination, a scan, blood tests and to talk about how your cancer is responding to the treatment and any side effects that you may be having. The total length of time you will be on the study is just over two and a half years.

      What happens if I’m unable to take part in this clinical trial?
      If your specific cancer type does not match what this clinical trial is looking at and/or the results of your blood tests are not in the range needed for the trial, you will not be able to take part in this clinical trial. Your doctor will suggest other treatments for your cancer that you can be given or other clinical trials that you may be able to take part in. You will not lose access to any of your regular care.

      For more information about this clinical trial see the For Expert tab on this page or follow this link to ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT03817853

      Trial Summary

      This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with previously untreated advanced follicular lymphoma (FL). The study has two phases: in the first phase, participants will receive the first cycle of obinutuzumab-based chemotherapy (G-chemo) induction therapy as usual with the first three infusions of obinutuzumab (1000 mg) administered at the regular infusion rate on Day 1, 8, and 15 of cycle 1. Phase 2 starts when participants who do not experience any Grade ≥ 3 infusion related reactions during the first cycle receive their first obintuzumab infusion given at the faster infusion rate in Cycle 2. For Cycle 2, Day 1 and all other following infusions (including maintenance), obinutuzumab will be administered at a faster infusion of 90-minute SDI, as long as the participant does not experience any Grade ≥ 3 infusion related reactions. The investigator is free to choose the chemotherapy for each participant (bendamustine, CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone/methylprednisolone], or CVP [cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone]). The total number of cycles of G-chemo induction therapy and the cycles length depends on the chemotherapy chosen for each participant.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT03817853 , MO40597 , 2018-003255-38 Trial Identifier
      Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine Treatments
      Advanced Follicular Lymphoma Condition
      Official Title

      A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Patients with previously untreated Stage III or IV FL or Stage II bulky disease scheduled to receive obinutuzumab plus chemotherapy due to at least one of the following criteria: a.) Bulky disease, defined as a nodal or extranodal (except spleen) mass

      ≥ 7 cm in the greatest diameter b.) Local symptoms or compromise of normal organ function due to progressive nodal disease or extranodal tumor mass c.) Presence of B symptoms (fever [> 38ºC], drenching night sweats, or unintentional weight loss of > 10% of normal body weight over a period of 6 months or less) d.) Presence of symptomatic extranodal disease (e.g., pleural effusions, peritoneal ascites) e.) Cytopenias due to underlying lymphoma (i.e., absolute neutrophil count < 1.0 × 109/L, hemoglobin < 10 g/dL, and/or platelet count < 100 × 109/L) f.) Involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3 cm g.) Symptomatic splenic enlargement

      • Histologically documented CD-20-positive FL, as determined by the local laboratory
      • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
      • Adequate hematologic function (unless abnormalities are related to FL)
      • Life expectancy of ≥ 12 months
      • For women who are not postmenopausal (≥ 12 consecutive months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 18 months after the last dose of obinutuzumab, for at least 3 months after the last dose of bendamustine or according to institutional guidelines for CHOP or CVP chemotherapy, whichever is longer
      • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm
      Exclusion Criteria
      • Relapsed / refractory FL
      • Prior treatment for FL with chemotherapy, radiotherapy, or immunotherapy
      • Grade IIIb FL
      • Histological evidence of transformation of FL into high-grade B-cell NHL
      • Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone/prednisolone/methylprednisolone (at a dose equivalent to >30 mg/day prednisone), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1
      • History of solid organ transplantation
      • History of anti-CD20 antibody therapy
      • History of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies
      • Known sensitivity or allergy to murine products
      • Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any of the study drugs
      • Active bacterial, viral, fungal, or other infection or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1
      • Positive test results for chronic HBV infection (defined as positive HBsAg serology)
      • Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
      • Known history of HIV positive status
      • History of progressive multifocal leukoencephalopathy (PML)
      • Vaccination with a live virus vaccine within 28 days prior to Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study
      • History of prior other malignancy with the exception of: a. Curatively treated carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal- or squamous-cell skin cancer, Stage I melanoma, or low-grade, early-stage localized prostate cancer b. Any previously treated malignancy that has been in remission without treatment for ≥ 2 years prior to enrollment
      • Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
      • Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1, Day 1, or anticipation of a major surgical procedure during the course of the study
      • Any of the following abnormal laboratory values:

      1.Creatinine > 1.5 × the upper limit of normal (ULN) (unless creatinine clearance normal) or creatinine clearance < 40 mL/min

      2.Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN

      3.Total bilirubin ≥ 1.5 × the ULN: Patients with documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0 × the ULN.

      4.International normalized ratio (INR) > 1.5 in the absence of therapeutic anticoagulation

      5.Partial thromboplastin time or activated partial thromboplastin time > 1.5 × ULN in the absence of a lupus anticoagulant

      • For patients who will be receiving CHOP: left ventricular ejection fraction (LVEF) < 50% by multigated acquisition (MUGA) scan or echocardiogram
      • Pregnant or lactating, or intending to become pregnant during the study
      • Any investigational therapy within 28 days prior to the start of Cycle 1
      • Positive test results for human T-lymphotropic virus 1 (HTLV-1)

       

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Follicular Lymphoma

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now